Sapna Lunj

Sapna Lunj

Auto-generated profile, based on publicly available information

Sapna Lunj

The University of Manchester, Division of Cancer Sciences, School of Medicine, Faculty of Biology Medicine and Health, Manchester, U.K.

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 August 2024 in Nature Reviews Urology
Verified
Journal Article
Closed access
PDF file
SLSapna Lunj
Sapna Lunj
TSTim Smith
Tim Smith
KRKimberley Jayne Reeves
Kimberley Jayne Reeves
FCFred Currell
Fred Currell
JHJamie Honeychurch
Jamie Honeychurch
ACAnanya Choudhury
Ananya Choudhury

13 October 2025 in Nature Reviews Urology
Verified
Journal Article
Closed access
PDF file
FCFraser Child
Fraser Child
SLSapna Lunj
Sapna Lunj
JGJulie Gough
Julie Gough
MHMartin J. Humphries
Martin J. Humphries
LBLuisa Vanesa Biolatti
Luisa Vanesa Biolatti
CQConrado Guerrero Quiles
Conrado Guerrero Quiles

4 April 2025 in bioRxiv
Verified
Preprint
Open access
CQConrado Guerrero Quiles
Conrado Guerrero Quiles
AGA. Julia Gonzalez
A. Julia Gonzalez
AFA. S. Foussat
A. S. Foussat
AOA. Olympitis
A. Olympitis
TLT. Lodhi
T. Lodhi
CWCatharine Mary Louise West
Catharine Mary Louise West
Our overarching aim was to determine how hypoxia affects the extracellular matrix (ECM). Transcriptomic analysis (21,941 patients; 10 cancer types) identified ECM remodelling as the predominant pathway affected by hypoxia. Multi-omics confirmed that hypoxia impacts ECM organisation and collagen degradation; 53 ECM genes were affected, of which 74% were HIF1/HIF2-regulated. Spatial transcriptomics highlighted different hypoxia remodelling processes in tumour and stroma. Five ECM genes commonly affected in tumour and in vitro constituted a signature. This signature was independently prognostic and independently predictive of radiotherapy benefit in multiple malignancies. Patients within either high or low hypoxic-ECM score tertiles benefited from radiotherapy versus surgery. Hypoxic ECMs generated in vitro increased adhesion and decreased migration of cancer cells, an effect enhanced by irradiation. Immunofluorescence demonstrated that hypoxia decreased collagen fibre number, and irradiation decreased cell-ECM interactions. Taken together, these findings demonstrate hypoxia induces pan-cancer ECM changes, directly impacting radiotherapy benefit.

15 June 2022 in Cancer Research
Verified
Journal Article
Open access
SLSapna Lunj
Sapna Lunj
HMHitesh Mistry
Hitesh Mistry
YSYeePei Song
YeePei Song
KPKamlesh Patel
Kamlesh Patel
HNHannah Nightingale
Hannah Nightingale
ACAnanya Choudhury
Ananya Choudhury
Targeted alpha therapy (TAT) is a type of radiotherapy (RT) that uses alpha-emitting radionuclides. These radionuclides have a natural affinity for areas of bone metastases (i.e., radium-223, Ra-223) or can label specific tumour targets (i.e., prostate-specific membrane antigen). Conventional photon irradiation (i.e., external beam) can activate or suppress immune responses. The resulting immune response is dictated by the release of soluble markers such as cytokines (i.e., IL-6) and damage associated molecular patterns, DAMPs (calreticulin). Less is known about the immune response induced by alpha-emitters. With increased interest in using TAT for cancer patients, it is important to gain a more in depth knowledge regarding the immune response of alpha emitters. Aim: Explore the systemic immune response of prostate cancer (PCa) patients to alpha-emitting RT by studying circulating cytokines, checkpoint molecules, matrix metalloproteinases (MMPs) and DAMPs. Methods: The cohort comprised of 43 patients with metastatic castration-resistant PCa treated with up to six four-weekly injections of the alpha emitter, Ra-223. We measured longitudinal changes in 61 plasma markers using the Luminex assay. The plasma markers included cytokines, checkpoint molecules and DAMPs. Results: Ra-223 induced longitudinal changes in 14 plasma markers over the course of treatment (T2-T6) compared with pre-treatment levels (T1). Most of the observed RT-induced changes occurred after four injections of Ra-223 (T5), where 9 of the 14 plasma markers changed significantly. The table summarises T5 findings (presented as mean concentration, pg/ml; statistical analysis using Wilcoxon matched-pairs signed rank test). Conclusion: Our data demonstrates that alpha-emitting RT induces systemic immune responses that can be measured in the plasma of patients. Given the diverse role of these markers, further study is needed to explore the biological implications of these systemic changes on patient outcome. Citation Format: Sapna Lunj, Hitesh Mistry, YeePei Song, Kamlesh Patel, Hannah Nightingale, Tim Smith, Peter Hoskin, Catharine West, Ananya Choudhury. Systemic immune response of prostate cancer patients to alpha-emitting radiotherapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 1289.

25 March 2026 in medRxiv
Verified
Preprint
Open access
PDF file
ADAnubhav Datta
Anubhav Datta
LBLuisa Vanesa Biolatti
Luisa Vanesa Biolatti
MRMark Reardon
Mark Reardon
KBKamilla Bigos
Kamilla Bigos
SLSapna Lunj
Sapna Lunj
ACAnanya Choudhury
Ananya Choudhury
Background: Tumour hypoxia is a major determinant of treatment resistance and poor prognosis in cervical cancer but remains difficult to assess in clinical practice. Gene expression signatures offer a potential means to characterise hypoxia-related biology. This study aimed to develop and validate a hypoxia-associated gene expression signature for cervical cancer. Methods: RNA sequencing was performed on five cervical cancer cell lines exposed to normoxia (21% O₂) and hypoxia (1% O₂). Differentially expressed genes were mapped to The Cancer Genome Atlas cervical cancer cohort (TCGA-CESC) to train a 55-gene hypoxia classifier using k-means clustering and Prediction Analysis for Microarrays. The model was validated in an institutional Manchester cohort (n=153) and two public datasets from Seoul (n=300) and Oslo (n=283). Results: The Manchester 55-gene signature was enriched for canonical hypoxia pathways. In the Manchester cohort, hypoxia classification correlated with advanced FIGO stage, nodal involvement, tumour size ≥ 4 cm, and hydronephrosis ( adjusted p <0.05). Hypoxic tumours showed reduced overall survival (OS) and progression-free survival (PFS) in all cohorts. In multivariable models, the signature remained independently prognostic for OS in both TCGA (HR 1.70, 95% CI 1.10–2.60, p =0.012) and Manchester (HR 1.95, 95% CI 1.08–3.51, p =0.026). A direct comparison with a published 6-gene hypoxia signature in the Oslo cohort demonstrated 71% concordance in classification. Conclusions: Our 55-gene signature should be tested prospectively in trials to assess its ability to stratify patients for hypoxia-targeted therapies.

23 July 2026 in Radiotherapy and Oncology
Verified
Journal Article
Open access
ADAnubhav Datta
Anubhav Datta
LBLuisa Vanesa Biolatti
Luisa Vanesa Biolatti
MRMark Reardon
Mark Reardon
KBKamilla Bigos
Kamilla Bigos
SLSapna Lunj
Sapna Lunj
ACAnanya Choudhury
Ananya Choudhury